The IRF2BPL Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from A-549 lung adenocarcinoma cells, featuring disruption of the IRF2BPL gene. This knockout model enables loss-of-function studies of IRF2BPL-mediated regulatory processes in a well-characterized epithelial host. The polyclonal format maintains genetic diversity while achieving widespread gene disruption across the cell pool, facilitating robust functional analyses without clonal selection bias. These cells provide a physiologically relevant platform for dissecting molecular pathways governed by IRF2BPL in both normal and disease states.
The A-549 cell line, established from a human pulmonary adenocarcinoma, serves as a model for alveolar type II epithelial cells. It is widely used in respiratory disease research and cancer biology, exhibiting sensitivity to interferon stimulation and expressing surfactant proteins characteristic of lung epithelium. The tumorigenic background and established signaling responses of A-549 cells make them an ideal host for interrogating gene functions in proliferation, apoptosis, and immune evasion, thereby enhancing the utility of the IRF2BPL knockout.
IRF2BPL encodes a transcriptional co-repressor that binds IRF2 to suppress interferon-stimulated genes (ISGs). Canonical interferon signaling, activated by type I IFNs or IFN-??, triggers STAT1 and IRF9 to induce ISRE-driven transcription. IRF2BPL antagonizes this by recruiting IRF2 to ISG promoters, thereby repressing immune response genes and influencing cell cycle regulators such as p21. Additionally, IRF2BPL interacts with CUL3 ubiquitin ligase components, implicating it in ubiquitin-mediated protein degradation. Key pathway nodes include upstream STAT1, downstream ISGs, and interacting factors IRF2 and IRF9.
In the A-549 lung cancer model, loss of IRF2BPL allows investigation of altered ISG expression dynamics and their impact on tumor cell behavior, including proliferation and sensitivity to interferon-induced apoptosis. This knockout system is valuable for studying how deregulated interferon signaling contributes to cancer phenotypes. Furthermore, because IRF2BPL mutations cause the neurodevelopmental disorder NEDAMSS, these epithelial cells can be used to explore conserved mechanistic pathways, offering insights into both oncogenic and neurological aspects of IRF2BPL function.
Experimental applications include RNA-seq or RT-qPCR profiling of ISG expression, western blot analysis of IRF2BPL and p21, MTT and annexin V assays to assess proliferation and apoptosis upon IFN-?? stimulation, and co-immunoprecipitation to confirm IRF2 interactions. The polyclonal knockout cells are suitable for drug screening targeting interferon signaling or cancer viability, as well as for mechanistic studies linking IRF2BPL to NEDAMSS pathology. For further details, please contact Ascent Research.
